Mineralocorticoid receptor antagonists (MRA), as a part of HF therapy, were reported for the first time in the study of PChR in the work by Giannoni et al. from 2008 [24] and became an integral component of HF therapy in later-revised studies. Here, NR3C2 is linked to hydrops fetalis.